PapGene is a molecular diagnostics company founded by Johns Hopkins cancer genomics researchers to commercialize genetic cytology tests for early cancer detection. Using cervical fluid from routine Pap tests, the company developed assays to detect ovarian, endometrial, and bladder cancers. PapGene's technology and team evolved into Thrive Earlier Detection Corp., which was acquired by Exact Sciences for $2.15 billion in 2021.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2016
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
